Skip to main content

Table 3 Clinical characteristics and engagement in care of patients with HIV infection whose medical records were reviewed, northeast Massachusetts, 2018 (N = 88)

From: An outbreak of HIV infection among people who inject drugs in northeastern Massachusetts: findings and lessons learned from a medical record review

 

na

%

Time since HIV infection diagnosis (as of June 30, 2018)

  < 6 months

13

15

 6 months to one year

29

33

 1- < 2 years

23

26

 2- < 5 years

18

20

 5+ years

5

6

Acute HIV infection documented during review period

10

11

In care since HIV diagnosis (one or more medical visits on or after date of diagnosis)

 Yes

81

92

 No

7

8

In care at CHC during review period (had at least 1 primary care visit in each review year)

 In care both years

50

57

 In care 2016/2017 only

8

9

 In care 2017/2018 only

30

34

On anti-retroviral therapy (ART) during review period

 Yes

68

77

 No

20

23

Initiated ART for the first time during the review period

 Yes

48

55

 No

40

45

Viral load (VL) test results during the review periodb

  > 1 VL test

84

95

 At least 2 VL tests

69

78

 No VL test

4

5

Viral load suppression (< 200 copies/mL)b (n = 84)

 Most recent VL suppressed

61

73

 Most recent VL unsuppressed

23

27

Viral load below limit of detection (< 20 copies/mL)b (n = 84)

 Most recent VL undetectable

50

60

 Most recent VL detectable

34

40

Hospitalized during the review period

 Yes

50

57

 No

38

43

Bacterial infection among hospitalized (N = 50)

 Yes

18

36

 No

32

64

Bacterial infections among hospitalized (N = 18) (categories not mutually exclusive)

 Bacteremia

8

44

 Endocarditis

2

11

 Osteomyelitis

0

0

 Cellulitis

11

61

 Other

3

17

Hepatitis C infectionc

 History documented (ever)

72

82

 Treatment documented (ever)

5

7

Hepatitis B immune statusc (through end of review period)

 Positive

58

66

 Negative

22

25

 Unknown

8

9

If Hepatitis B negative or unknown (n = 30), received 3 HBV vaccine doses

 Yes

8

27

 No

22

73

Sexually transmitted infections during review periodd

 Yes

8

9

 No

80

91

Prescribed any of the following medications during the review period

 Any Opioid

5

6

 Fentanyl

0

0

 Oxycodone

0

0

 Methadone

26

30

 Naltrexone

13

15

 Buprenorphine

0

0

 Buprenorphine/naloxone

22

25

 Benzodiazepine or another anxiolytic

7

8

 Antidepressant

36

41

 Antipsychotic

18

21

  1. aAs determined through medical record review, and HIV surveillance data (for viral load measures, only) reported to the Massachusetts Department of Public Health through October 31, 2018. Medical record review period was May 1, 2016 through date of data abstraction (abstraction done May 17 to June 6, 2018)
  2. bBased on information from chart review supplemented with HIV surveillance data
  3. cHepatitis B immune status definitions: positive: if positive result for surface antigen, surface antibody, core antibody, or presence of HBV DNA; negative: if negative result for both surface antibody and core antibody or HBV DNA negative
  4. dDiagnosed sexually transmitted infections include gonorrhea (n = 3), chlamydia (n = 3), and syphilis (n = 2)